

MIEBO® PA Checklist

Miebo[®]
(perfluorohexyloctane
ophthalmic solution)

Help your appropriate patients gain access to MIEBO

Use this checklist as a guide when completing a prior authorization (PA) request to help ensure necessary information is documented.* Incomplete or missing information in any of the following categories may result in a PA denial.

DESIRED MEDICATION

MIEBO® (perfluorohexyloctane ophthalmic solution)

30-day supply (3 mL in a 5 mL bottle)

PATIENT'S CLINICAL RECORDS (including ocular history)

Patient-reported dry eye symptoms, such as¹:

- Irritation
- Tearing
- Burning
- Stinging
- Dry or foreign body sensation
- Mild itching
- Photophobia
- Blurry vision
- Contact lens intolerance
- Redness
- Mucous discharge
- Increased frequency of blinking
- Eye fatigue
- Symptoms that fluctuate and/or worsen later in the day

Clinical observations, such as¹:

- Inflammation
- Decreased tear production
- Severity of disease

Clinical diagnosis of dry eye disease (DED), such as:

- Date of diagnosis
- Valid ICD-10 diagnosis code with the full 7 characters and description
- Diagnostic testing and results, which may include at least 1 of the following¹:
 - External eye examination
 - Tear film breakup time (TBUT)
 - Aqueous tear production (Schirmer's test)
 - Ocular surface staining
 - Fluorescein dye disappearance test/tear function index
 - Lacrimal gland function
 - Matrix metalloproteinase-9 (MMP-9) test
 - Tear osmolarity
 - Slit lamp exam

Prior treatment history for DED:

- Drugs tried and failed (failure may require inadequate response to at least 2 formulary alternative and/or over-the-counter medications based on the insurance plan's policy [eg, artificial tears, lubricants, gels, or ointments]), including the following information:
 - Product name
 - Dose
 - Frequency of use
 - Dates of treatment
 - Response to treatment
 - Outcome

Impact of DED on visual function, such as the following¹:

- Reading
- Daily activities
- Driving
- Productivity at work
- Social and physical functioning
- Quality of life

Attach a copy of the letter of medical necessity and patient's medical records, including chart notes (when required by the plan)

Ensure prescriber signature is included (when required by the plan)

*This information is for reference only. Bausch + Lomb cannot guarantee insurance coverage or reimbursement. Coverage and reimbursement may vary significantly by payer, plan, patient, and setting of care. It is the sole responsibility of the eye care professional to select the proper codes and ensure the accuracy of all statements used in seeking coverage and reimbursement.

ICD=International Classification of Diseases.

INDICATION

MIEBO® (perfluorohexyloctane ophthalmic solution) is indicated for the treatment of the signs and symptoms of dry eye disease.

IMPORTANT SAFETY INFORMATION

- MIEBO should not be administered while wearing contact lenses. Contact lenses should be removed before use and for at least 30 minutes after administration of MIEBO

Please see continued Important Safety Information on reverse side. Click [here](#) for full Prescribing Information for MIEBO.

BAUSCH + LOMB

MIEBO® ICD-10 Coding

These diagnosis code examples are provided for general informational purposes only and are not intended to be directive, a guarantee of coverage, or a substitute for an independent clinical decision.



EXAMPLE ICD-10 CODES FOR DRY EYE DIAGNOSIS²

Description	Right	Left	Bilateral	Unspecified
Dry eye syndrome of lacrimal gland	H04.121	H04.122	H04.123	H04.129
Unspecified epiphora	H04.201	H04.202	H04.203	H04.209
Unspecified superficial keratitis	H16.101	H16.102	H16.103	H16.109
Punctate keratitis	H16.141	H16.142	H16.143	H16.149
Unspecified keratoconjunctivitis	H16.201	H16.202	H16.203	H16.209
Keratoconjunctivitis sicca, not specified as Sjögren's	H16.221	H16.222	H16.223	H16.229
Other keratoconjunctivitis	H16.291	H16.292	H16.293	H16.299
Sicca syndrome (Sjögren), unspecified - M35.00				
Sicca syndrome (Sjögren) with keratoconjunctivitis - M35.01				

EXAMPLE ICD-10 CODES FOR DRY EYE SYMPTOMS²

Description	Right	Left	Bilateral	Unspecified
Visual discomfort	H53.141	H53.142	H53.143	H53.149
Other visual disturbances - H53.8				

IMPORTANT SAFETY INFORMATION (cont'd)

- Instruct patients to instill one drop of MIEBO into each eye four times daily
- The safety and efficacy in pediatric patients below the age of 18 have not been established
- The most common ocular adverse reaction was blurred vision (1% to 3% of patients reported blurred vision and conjunctival redness)

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Click [here](#) for full Prescribing Information for MIEBO.

References: 1. Amescua G, Ahmad S, Cheung AY, et al. Dry Eye Syndrome Preferred Practice Pattern®. *Ophthalmology*. 2024;131(4):P1-P49. doi:10.1016/j.optha.2023.12.041 2. CMS.gov. 2024 ICD-10-CM Accessed December 11, 2023. <https://www.cms.gov/medicare/coding-billing/icd-10-codes/2024-icd-10-cm>